Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by FarmerBetsyon Nov 02, 2023 11:15am
267 Views
Post# 35713573

Let me get this Promisneurosciences into Phase 1 correct?

Let me get this Promisneurosciences into Phase 1 correct?Let me see if i understand this correctly?
They recieve the IND filing in May after many delays which i assume points out a plan on how they can proceed into the clinic?

Then psoted on July 27th, after recieving the IND ,Promis Corporate overview states:

"PMN310 First-in-Human Single Ascending Dose PK Study 22 • Inpatient single dose escalation study of PMN310 and placebo, N=8 per cohort (6:2), in healthy volunteers • Planned fixed IV doses of PMN310 equivalent to approximately 2.5 - 60 mg/kg; high dose will be informed by results of early cohorts • Data expected to be available mid-2023"

Then on 2023-10-07 heading into the 7th month after recieving IND approval they begin to post on the Gov Clinical trial site, not yet recruiting. 

So i'll post this question again Elliot? After recieving the IND why were they not in the Clinic in May?

Not enought time to prepare for 8 volunteers, someone earlier said it was the cost they had to do another PP back in August, MPT and BOD's participating.  Really?

"Participants seeking only new healthy volunteer trials tended to screen for three studies per year, participate in one or two studies, and earn roughly US$4000 annually."

Mike Gordon and Jeremy Sclar of the Boston Group must be laughing and laughing as they continue to add shares through PP's at company all time low prices. For the Boston group and MPT it's all about delay, delay, delay, and now another year with no meaningful news  but in the mean time they will probably continue to acquire cheap, cheap stock!

On the bright side the estimated completion date of July next year coincides perfectly with another Alzheimers conference, in which they might be able to present some information on PMN 310 an antibody developed for Alzheimers disease.  When asked by Analysts how it worked in Alzheimers they will have to respond with we don't actually  know we didn't test it in Alzheimers patients but we also we didn't test it in Cancer or Covid pateints just healthy volunteers. The Boston group executing another stock sleeper!! 







<< Previous
Bullboard Posts
Next >>